|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Vascular smooth muscle cells derives from atherosclerotic human arteries exhibit greater adhesion,migration,and proliferation than venous cells显示文摘 | Faries P L Rohan D I Wyers M C | 2002 | J Surg Res2002，104，： | 1 |
| 2 | Vascular smooth muscle cells derived frorn atherosclerotic human arteries exhibit greater adhesion,rnigration,and proliferation than venous cells显示文摘 | FARIES P L ROHAN D I WYERS M C | 2002 | J Surg Res2002，104，： | 1 |
| 3 | Acetylaiton of anisole by acetic anhydride over a HBEA zeolites-origin of deactivation of the catalyst显示文摘 | ROHAN D CANAFF C CANAFF C GUISNET M | 1998 | J Catal1998，177，2： | 1 |
| 4 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 5 | Secondary lymphoid-tissue chemokine( SLC ) is chemotatic for mature dendritic cells 显示文摘 | Chan V W Kothakota S Rohan M C | 1999 | Blood1999，93，11： | 1 |
| 6 | Changes in the concentration of mRNAs for the inhibin subunits in ovarian follicles after administration of gonadotropins to progestin treated ewe显示文摘 | ROHAN R M REXROAD C E J R GUTHRIE H D | 1991 | Domest Anim Endocrinol1991，8，： | 1 |
| 7 | Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion,migration,and proliferation than venous cells显示文摘 | FARIES P L ROHAN D I WYERS M C | 2002 | J Surg Res2002，104，： | 1 |
| 8 | Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion,migration,and proliferation than venous cells显示文摘 | Faries P L Rohan D I Wyers M C | 2002 | J Surg Res2002，104，1： | 1 |
| 9 | Osteitic bone: a surrogate marker of eosinophilia in chronic rhinosinusitis 显示文摘 | Komkiat S Rohan M David C | 2012 | Rhinology2012，50，3： | 1 |
| 10 | Land tenure security Revisi- ting andrefining the concept for Sub -Saharan Africa's rural poor 显示文摘 | Marie C Dushimyimana S Rohan M | | LandUse Policy0，2014，： | 1 |
| 11 | Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion,migration,and proliferation than venous cells 显示文摘 | Faries P L Rohan D I Wyers M C | 2002 | J Surg Res2002，104，： | 1 |
| 12 | One-year survival in recipients older than 50 bridged to heart transplant with Impella 5.5 via axillary approach显示文摘BACKGROUND Optimizing patients with advanced heart failure before orthotopic heart transplantation(OHT), especially in patients greater than 50 years old, is imperative to achieving successful post-transplant outcomes. Complications are well-described for patients bridged to transplant(BTT) with durable left ventricular assist device(LVAD) support. Given the lack of data available in older recipients after the recent increase in mechanical support use, we felt it crucial to report our center’s one-year outcomes in older recipients after heart transplantation with percutaneously placed Impella 5.5 as a BTT.METHODS Forty-nine OHT patients were supported with the Impella 5.5 intended as a bridge between December 2019 and October 2022 at Mayo Clinic in Florida. Data were extracted from the electronic health record at baseline and during their transplant episode of care after Institutional Review Boards approval as exempt for retrospective data collection.RESULTS Thirty-eight patients aged 50 or older were supported with Impella 5.5 as BTT. Ten patients underwent heart and kidney transplantation within this cohort. The median age at OHT was 63(58–68) years, with 32 male(84%) and six female patients(16%). Etiology was divided into ischemic(63%) and non-ischemic cardiomyopathy(37%). The baseline median ejection fraction was 19%(15–24). Most patients were in blood group O(60%), and 50% were diabetic. The average duration of support was 27 days(range 6–94). The median duration of follow-up is 488 days(185–693). For patients that have reached the 1-year follow-up timeframe(22 of 38, 58%), the 1-year post-transplant survival is 95%.CONCLUSION Our single-center data provides awareness for using the Impella 5.5 percutaneously placed axillary support device in older heart failure patients in cardiogenic shock as a bridge to transplantation. One-year survival outcomes after heart transplantation are excellent despite the older recipient’s age and prolonged pre-transplant support. | Smit Paghdar Smruti Desai Ji-Min Jang Jose Ruiz Sharan Malkani Parag Patel Daniel S Yip Juan C Leoni Jose Nativi Basar Sareyyupoglu Kevin Landolfo Si Pham Rohan M Goswami | 2023 | Journal of Geriatric Cardiology2023，20，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员